循环胃泌素原（hPG）作为高级别胶质瘤的血液生物标志物：一项初步研究。
hPG (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study.
作者信息
Casile Melanie, Passildas Judith, Vire Bérengère, Molnar Ioana, Durando Xavier
机构信息
INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France.
UMR 501, Clinical Investigation Centre, Clermont-Ferrand, France.
出版信息
Front Neurol. 2023 Jan 11;13:1073476. doi: 10.3389/fneur.2022.1073476. eCollection 2022.
BACKGROUND
Currently, the long-term prognosis and survival rate of patients with high-grade glial tumors remains poor and there are no biomarkers. hPG (circulating progastrin) secreted into the blood by tumor cells has been widely studied in colorectal cancer. Its involvement in tumorigenesis has been demonstrated in the literature. Moreover, according to a recent study, hPG is expressed in the blood of cancer patients at a significantly higher concentration than in the control group composed of healthy blood donors.
METHODS
The PROGLIO study is a pilot, single-center, longitudinal study that primarily seeks to evaluate circulating plasma hPG concentrations over time in patients with high-grade glial tumors. A fasting blood sample will be taken on the start and end day of radiotherapy and during the adjuvant chemotherapy (every 3 cycles). Follow-up monitoring will be performed for 9 months, with a blood sample taken every 3 months on the day of the follow-up MRI. The study plans to recruit 30 patients and recruitment started in February 2022.
TRIAL REGISTRATION
ClinicalTrials.gov, ID NCT05157594; registered on October 27, 2021.
背景
目前，高级别胶质瘤患者的长期预后和生存率仍然很差，且尚无生物标志物。肿瘤细胞分泌到血液中的循环胃泌素原（hPG）在结直肠癌中已得到广泛研究。其参与肿瘤发生已在文献中得到证实。此外，根据最近一项研究，癌症患者血液中hPG的表达浓度明显高于由健康献血者组成的对照组。
方法
PROGLIO研究是一项试点、单中心纵向研究，主要旨在评估高级别胶质瘤患者随时间变化的循环血浆hPG浓度。在放疗开始和结束日以及辅助化疗期间（每3个周期）采集空腹血样。将进行9个月的随访监测，在随访MRI当天每3个月采集一次血样。该研究计划招募30名患者，于2022年2月开始招募。
试验注册
ClinicalTrials.gov，ID NCT05157594；于2021年10月27日注册。
Zotero 插件